
1. j virol. 2012 sep;86(18):10218-20. doi: 10.1128/jvi.00353-12. epub 2012 jul 11.

ccr5 mutations distinguish n-terminal modifications rantes (ccl5) agonist
versus antagonist activity.

choi wt(1), nedellec r, coetzer m, colin p, lagane b, offord re, hartley o,
mosier de.

author information: 
(1)department immunology microbial science, scripps research
institute, la jolla, california, usa.

ccr5 major hiv-1 entry coreceptor. rantes/ccl5 analogs potent
inhibitors infection native chemokines; one class activates and
internalizes ccr5, one neither activates internalizes, third partially 
internalizes without activation. show mutations ccr5
transmembrane domains differentially impact activity three inhibitor
classes, suggesting transmembrane region ccr5, key interaction site
for inhibitors, sensitive molecular switch, modulating receptor activity.

doi: 10.1128/jvi.00353-12 
pmcid: pmc3446584
pmid: 22787219  [indexed medline]

